Enesi Pharma and Imperial College London Collaborate to Develop Thermostable RNA Vaccines with Potential to Eliminate Cold Chain and Transform Global Vaccination Logistics for COVID-19

OXFORD, England and LONDON, Dec. 18, 2020 /PRNewswire/ --A Enesi Pharma ("Enesi"), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVaxA® technologies, announces it is collaborating with Prof. Robin Shattock, a leading infectious disease and vaccine expert, and his group at Imperial College London ("Imperial"), to develop RNA vaccines, including against SARS-CoV-2, that are stable at ambient temperatures and up to 40o Celsius (104o Fahrenheit). The ability to create such vaccines could minimize or eliminate the cold chain requirements for global deployment and mass vaccination programmes with RNA-based vaccines. The collaboration will investigate the potential of combining Enesi's ImplaVaxA® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial's self-amplifying RNA (saRNA) technology and novel Polyplex DNA/RNA stabilisation technologies. ImplaVaxA® technology enables the development of solid dose vaccines of a fixed (unit) dose that are designed to be delivered using a needle-free device into the dermal layer of the skin and with minimal administrator training.An early phase of the collaboration a?? to assess the feasibility of creating a thermostable and immunogenic, solid dose DNA vaccine employing Enesi' ImplaVaxA® and Imperial's Polyplex technologies a?? has been completed successfully. Based on these results, Enesi and Imperial are advancing their collaboration into a new phase to develop and evaluate the effectiveness of RNA vaccines using saRNA, Polyplex and ImplaVax technologies.The successful production of a solid dose RNA vaccine, and demonstration of an appropriate immune response could lead to a further partnership to develop at pace an ImplaVaxA® version of Imperial's RNA vaccine against SARS-CoV-2, which is based on the virus' spike protein and is being investigated in a Phase I/II trial in over 400 healthy subjects.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »